{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:28:41Z","timestamp":1793878121293,"version":"4.7.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["MOH-00535\/MOH-OFYIRG19nov-002"],"award-info":[{"award-number":["MOH-00535\/MOH-OFYIRG19nov-002"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Despite SARS-CoV-2 vaccines eliciting systemic neutralising antibodies (nAbs), breakthrough infections still regularly occur. Infection helps to generate mucosal immunity, possibly reducing disease transmission. Monitoring mucosal nAbs is predominantly restricted to lab-based assays, which have limited application to the public. In this multi-site study, we used lateral-flow surrogate neutralisation tests to measure mucosal and systemic nAbs in vaccinated and breakthrough infected individuals in Australia and Singapore. Using three lateral flow assays to detect SARS-CoV-2 nAbs, we demonstrated that nasal mucosal nAbs were present in 71.4 (95% CI 56.3\u201382.9%) to 85.7% (95% CI 71.8\u201393.7%) of individuals with breakthrough infection (positivity rate was dependent upon the type of test), whereas only 20.7 (95% CI 17.1\u201349.4%) to 34.5% (95% CI 19.8\u201352.7%) of vaccinated individuals without breakthrough infection had detectible nasal mucosal nAbs. Of the individuals with breakthrough infection, collective mucosal anti-S antibody detection in confirmatory assays was 92.9% (95% CI 80.3\u201398.2%) of samples, while 72.4% (95% CI 54.1\u201385.5%) of the vaccinated individuals who had not experienced a breakthrough infection were positive to anti-S antibody. All breakthrough infected individuals produced systemic anti-N antibodies; however, these antibodies were not detected in the nasal cavity. Mucosal immunity is likely to play a role in limiting the transmission of SARS-CoV-2 and lateral flow neutralisation tests provide a rapid readout of mucosal nAbs at the point-of-care.<\/jats:p>","DOI":"10.1038\/s41598-023-47613-8","type":"journal-article","created":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T13:04:40Z","timestamp":1700485480000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Use of a point-of-care test to rapidly assess levels of SARS-CoV-2 nasal neutralising antibodies in vaccinees and breakthrough infected individuals"],"prefix":"10.1038","volume":"13","author":[{"given":"Chee Wah","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan Kok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline","family":"Prestedge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell","family":"Batty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun Yan","family":"Mah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"O\u2019Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-Fa","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Kilby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle E.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,20]]},"reference":[{"key":"47613_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41392-022-01009-8","volume":"7","author":"G Balint","year":"2022","unstructured":"Balint, G., Voros-Horvath, B. & Szechenyi, A. Omicron: Increased transmissibility and decreased pathogenicity. Signal Transduct. Target Ther. 7, 151. https:\/\/doi.org\/10.1038\/s41392-022-01009-8 (2022).","journal-title":"Signal Transduct. Target Ther."},{"key":"47613_CR2","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1038\/s41586-022-04441-6","volume":"603","author":"PJ Halfmann","year":"2022","unstructured":"Halfmann, P. J. et al. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603, 687\u2013692. https:\/\/doi.org\/10.1038\/s41586-022-04441-6 (2022).","journal-title":"Nature"},{"key":"47613_CR3","unstructured":"Statement on the fifteenth meeting of the IHR (2005) Emergency Committee on the COVID-19 pandemic. https:\/\/www.who.int\/news\/item\/05-05-2023-statement-on-the-fifteenth-meeting-of-the-international-health-regulations-(2005)-emergency-committee-regarding-the-coronavirus-disease-(covid-19)-pandemic#:~:text=The%20WHO%20Director%2DGeneral%20concurs,of%20international%20concern%20(PHEIC) (2022)."},{"key":"47613_CR4","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","volume":"27","author":"DS Khoury","year":"2021","unstructured":"Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat. Med. 27, 1205\u20131211. https:\/\/doi.org\/10.1038\/s41591-021-01377-8 (2021).","journal-title":"Nat. Med."},{"key":"47613_CR5","doi-asserted-by":"publisher","first-page":"e52","DOI":"10.1016\/S2666-5247(21)00267-6","volume":"3","author":"D Cromer","year":"2022","unstructured":"Cromer, D. et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: A meta-analysis. Lancet Microbe 3, e52\u2013e61. https:\/\/doi.org\/10.1016\/S2666-5247(21)00267-6 (2022).","journal-title":"Lancet Microbe"},{"key":"47613_CR6","doi-asserted-by":"publisher","first-page":"eabo2523","DOI":"10.1126\/science.abo2523","volume":"378","author":"T Mao","year":"2022","unstructured":"Mao, T. et al. Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses. Science 378, eabo2523. https:\/\/doi.org\/10.1126\/science.abo2523 (2022).","journal-title":"Science"},{"key":"47613_CR7","doi-asserted-by":"publisher","first-page":"e336","DOI":"10.1093\/cid\/ciac448","volume":"76","author":"Y Lin","year":"2023","unstructured":"Lin, Y. et al. Nasal spray of neutralizing monoclonal antibody 35B5 confers potential prophylaxis against severe acute respiratory syndrome coronavirus 2 variants of concern: A small-scale clinical trial. Clin. Infect. Dis. 76, e336\u2013e341. https:\/\/doi.org\/10.1093\/cid\/ciac448 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"47613_CR8","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/S1473-3099(22)00834-9","volume":"23","author":"U Marking","year":"2023","unstructured":"Marking, U. et al. 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection. Lancet Infect. Dis. 23, 150\u2013152. https:\/\/doi.org\/10.1016\/S1473-3099(22)00834-9 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"47613_CR9","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/s41587-020-0631-z","volume":"38","author":"CW Tan","year":"2020","unstructured":"Tan, C. W. et al. A SARS-CoV-2 surrogate virus neutralization test based on antibody-mediated blockage of ACE2-spike protein-protein interaction. Nat. Biotechnol. 38, 1073\u20131078. https:\/\/doi.org\/10.1038\/s41587-020-0631-z (2020).","journal-title":"Nat. Biotechnol."},{"key":"47613_CR10","doi-asserted-by":"publisher","first-page":"1127401","DOI":"10.3389\/fimmu.2023.1127401","volume":"14","author":"S Liu","year":"2023","unstructured":"Liu, S. et al. Comparison of the mucosal and systemic antibody responses in Covid-19 recovered patients with one dose of mRNA vaccine and unexposed subjects with three doses of mRNA vaccines. Front. Immunol. 14, 1127401. https:\/\/doi.org\/10.3389\/fimmu.2023.1127401 (2023).","journal-title":"Front. Immunol."},{"key":"47613_CR11","doi-asserted-by":"publisher","first-page":"104402","DOI":"10.1016\/j.ebiom.2022.104402","volume":"87","author":"F Liew","year":"2023","unstructured":"Liew, F. et al. SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. EBioMedicine 87, 104402. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104402 (2023).","journal-title":"EBioMedicine"},{"key":"47613_CR12","doi-asserted-by":"publisher","first-page":"104248","DOI":"10.1016\/j.ebiom.2022.104248","volume":"84","author":"D Christensen","year":"2022","unstructured":"Christensen, D. et al. Protection against SARS-CoV-2 transmission by a parenteral prime-Intranasal boost vaccine strategy. EBioMedicine 84, 104248. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104248 (2022).","journal-title":"EBioMedicine"},{"key":"47613_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/s41392-023-01423-6","volume":"8","author":"Q Wang","year":"2023","unstructured":"Wang, Q. et al. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants. Signal Transduct. Target Ther. 8, 167. https:\/\/doi.org\/10.1038\/s41392-023-01423-6 (2023).","journal-title":"Signal Transduct. Target Ther."},{"key":"47613_CR14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1080\/22221751.2022.2053365","volume":"11","author":"JY Lam","year":"2022","unstructured":"Lam, J. Y. et al. A nasal omicron vaccine booster elicits potent neutralizing antibody response against emerging SARS-CoV-2 variants. Emerg. Microbes Infect. 11, 964\u2013967. https:\/\/doi.org\/10.1080\/22221751.2022.2053365 (2022).","journal-title":"Emerg. Microbes Infect."},{"key":"47613_CR15","doi-asserted-by":"publisher","first-page":"35895","DOI":"10.1021\/acsami.3c05456","volume":"15","author":"L Xiao","year":"2023","unstructured":"Xiao, L. et al. Mucosal SARS-CoV-2 nanoparticle vaccine based on mucosal adjuvants and its immune effectiveness by intranasal administration. ACS Appl. Mater. Interfaces 15, 35895\u201335905. https:\/\/doi.org\/10.1021\/acsami.3c05456 (2023).","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"47613_CR16","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1080\/17425247.2023.2263363","volume":"20","author":"F Sonvico","year":"2023","unstructured":"Sonvico, F. et al. Nasal delivery as a strategy for the prevention and treatment of COVID-19. Expert. Opin. Drug. Deliv. 20, 1115\u20131130. https:\/\/doi.org\/10.1080\/17425247.2023.2263363 (2023).","journal-title":"Expert. Opin. Drug. Deliv."},{"key":"47613_CR17","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2210063","volume":"388","author":"BE McGarry","year":"2023","unstructured":"McGarry, B. E., Gandhi, A. D. & Barnett, M. L. Covid-19 surveillance testing and resident outcomes in nursing homes. N. Engl. J. Med. 388, 1101\u20131110. https:\/\/doi.org\/10.1056\/NEJMoa2210063 (2023).","journal-title":"N. Engl. J. Med."},{"key":"47613_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/vaccines9101092","volume":"2021","author":"JL Bayart","year":"2021","unstructured":"Bayart, J. L. et al. Waning of IgG, total and neutralizing antibodies 6 months post-vaccination with BNT162b2 in healthcare workers. Vaccines (Basel) 2021, 9. https:\/\/doi.org\/10.3390\/vaccines9101092 (2021).","journal-title":"Vaccines (Basel)"},{"key":"47613_CR19","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41541-022-00504-x","volume":"7","author":"DJ Barbeau","year":"2022","unstructured":"Barbeau, D. J. et al. Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S. NPJ Vaccines 7, 77. https:\/\/doi.org\/10.1038\/s41541-022-00504-x (2022).","journal-title":"NPJ Vaccines"},{"key":"47613_CR20","doi-asserted-by":"publisher","first-page":"e240","DOI":"10.1016\/S2666-5247(21)00025-2","volume":"2","author":"WN Chia","year":"2021","unstructured":"Chia, W. N. et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: A longitudinal study. Lancet Microbe 2, e240\u2013e249. https:\/\/doi.org\/10.1016\/S2666-5247(21)00025-2 (2021).","journal-title":"Lancet Microbe"},{"key":"47613_CR21","doi-asserted-by":"publisher","first-page":"eabn8057","DOI":"10.1126\/scitranslmed.abn8057","volume":"14","author":"JP Evans","year":"2022","unstructured":"Evans, J. P. et al. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Sci. Transl. Med. 14, eabn8057. https:\/\/doi.org\/10.1126\/scitranslmed.abn8057 (2022).","journal-title":"Sci. Transl. Med."},{"key":"47613_CR22","doi-asserted-by":"publisher","first-page":"e84","DOI":"10.1056\/NEJMoa2114583","volume":"385","author":"EG Levin","year":"2021","unstructured":"Levin, E. G. et al. Waning immune humoral response to BNT162b2 Covid-19 vaccine over 6 months. N. Engl. J. Med. 385, e84. https:\/\/doi.org\/10.1056\/NEJMoa2114583 (2021).","journal-title":"N. Engl. J. Med."},{"key":"47613_CR23","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3325\/cmj.2021.62.630","volume":"62","author":"B Kolaric","year":"2021","unstructured":"Kolaric, B., Ambriovic-Ristov, A., Tabain, I. & Vilibic-Cavlek, T. Waning immunity six months after BioNTech\/Pfizer COVID-19 vaccination among nursing home residents in Zagreb, Croatia. Croat. Med. J. 62, 630\u2013633. https:\/\/doi.org\/10.3325\/cmj.2021.62.630 (2021).","journal-title":"Croat. Med. J."},{"key":"47613_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.3390\/vaccines10010072","volume":"10","author":"R Zhang","year":"2022","unstructured":"Zhang, R. et al. Immunogenicity of a heterologous prime-boost COVID-19 vaccination with mRNA and inactivated virus vaccines compared with homologous vaccination strategy against SARS-CoV-2 variants. Vaccines (Basel) 10, 72. https:\/\/doi.org\/10.3390\/vaccines10010072 (2022).","journal-title":"Vaccines (Basel)"},{"key":"47613_CR25","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/vaccines10040510","volume":"10","author":"J Tuells","year":"2022","unstructured":"Tuells, J. et al. Detection of neutralizing antibodies against SARS-CoV-2 post-vaccination in health care workers of a large tertiary hospital in spain by using a rapid test LFIC and sVNT-ELISA. Vaccines (Basel) 10, 4. https:\/\/doi.org\/10.3390\/vaccines10040510 (2022).","journal-title":"Vaccines (Basel)"},{"key":"47613_CR26","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad385","author":"J Froberg","year":"2023","unstructured":"Froberg, J. et al. Primary exposure to SARS-CoV-2 via infection or vaccination determines mucosal antibody-dependent ACE2 binding inhibition. J. Infect. Dis. https:\/\/doi.org\/10.1093\/infdis\/jiad385 (2023).","journal-title":"J. Infect. Dis."},{"key":"47613_CR27","doi-asserted-by":"publisher","first-page":"100129","DOI":"10.1016\/j.jacig.2023.100129","volume":"2","author":"KT Cao","year":"2023","unstructured":"Cao, K. T. et al. SARS-CoV-2 mRNA vaccination induces an intranasal mucosal response characterized by neutralizing antibodies. J. Allergy Clin. Immunol. Glob. 2, 100129. https:\/\/doi.org\/10.1016\/j.jacig.2023.100129 (2023).","journal-title":"J. Allergy Clin. Immunol. Glob."},{"key":"47613_CR28","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12985-023-02113-z","volume":"20","author":"A Ishizaka","year":"2023","unstructured":"Ishizaka, A. et al. Research article antibody induction and immune response in nasal cavity by third dose of SARS-CoV-2 mRNA vaccination. Virol. J. 20, 146. https:\/\/doi.org\/10.1186\/s12985-023-02113-z (2023).","journal-title":"Virol. J."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47613-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47613-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T12:06:35Z","timestamp":1701086795000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-47613-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,20]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["47613"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-47613-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,20]]},"assertion":[{"value":"25 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20263"}}